NY-ESO-1 expression and immunogenicity in prostate cancer patients;Etude de l'expression et de l'immunogénécité de NY-ESO-1 chez les patients atteints du cancer de la prostate

Tunisie Medicale

Volumn 89, Issue 10, 2011, Pages 779-783

  Gati, Asma ^a,c   Lajmi, Nesrine ^a,c   Derouiche, Amine ^b,c   Marrakchi, Raja ^a,c   Chebil, Mohamed ^b,c   Benammar Elgaaied, Amel ^a,c  

^a FACULTÉ DES SCIENCES DE TUNIS   (Tunisia)

^b CHARLES NICOLLE HOSPITAL   (Tunisia)

^c UNIVERSITY OF TUNIS EL MANAR   (Tunisia)

Author keywords

Cancer testis antigen; Immunotherapy; NY ESO 1; Prostate cancer

Indexed keywords

MESSENGER RNA; NY ESO 1 ANTIGEN; TUMOR MARKER;

ADULT; AGED; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; MALE; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

AGED; AGED, 80 AND OVER; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 80355139380     PISSN: 00414131     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun M J. Cancer statistics, 2007. CA Cancer J Clin. 2007; 57: 43-66.
2. Hadaschik B A, Gleave M E. Therapeutic options for hormonerefractory prostate cancer in 2007. Urol Oncol 2007; 25:413-19.
3. Begley J, Ribas A. Targeted therapies to improve tumor immunotherapy. Clin Cancer Res 2008; 14:4385-91.
4. Wong M K. The current role of immunotherapy for renal cell carcinoma in the era of targeted therapeutics. Curr Oncol Rep 2008; 10:259-63.
5. Scanlan M J, Gure A O, Jungbluth A A, Old L J, Chen Y T. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev 2002; 188:22-32.
6. Jager E, Nagata Y, Gnjatic S, et al. Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc Natl Acad Sci U S A 2000; 97:4760-65.
7. Chen Y T, Scanlan M J, Sahin U, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A 1997; 94:1914-18.
8. Sugita Y, Wada H, Fujita S, et al. NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors. Cancer res 2004; 64:2199-204.
9. Odunsi K, Jungbluth A A, Stockert E, et al. NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Res 2003; 63:6076-83.
10. Zhang W M, Xiao G, Zhang M, Guo A L, Dong Y, Wen J M. [Expression of NY-ESO-1 and LAGE-1 cancer-testis antigens in hepatocellular carcinoma]. Zhonghua bing li xue za zhi Chinese journal of pathology 2005; 34:202-205.
11. Konishi J, Toyooka S, Aoe M, et al. The relationship between NYESO-1 mRNA expression and clinicopathological features in nonsmall cell lung cancer. Oncol Rep 2004; 11:1063-67.
12. Fujita S, Wada H, Jungbluth AA, et al. NY-ESO-1 expression and immunogenicity in esophageal cancer. Clin Cancer Res 2004; 10:6551-58.
13. Jager D, Stockert E, Karbach J, et al. Urine antibody against human cancer antigen NY-ESO-1. Cancer Immun 2002; 2:10.
14. Gnjatic S, Nishikawa H, Jungbluth AA, et al. NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res. 2006; 95:1-30.
15. Dunn G P, Bruce A T, Ikeda H, Old L J, Schreiber R D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3:991-998.
16. Stockert E, Jager E, Chen Y T, et al. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 1998; 187:1349-54.
17. Gnjatic S, Atanackovic D, Jager E, et al. Survey of naturally ccurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses. Proc Natl Acad Sci U S A 2003; 100:8862-67.
18. Hudolin T, Juretic A, Spagnoli G C, et al. Immunohisto chemicale xpression of tumor antigens MAGE-A1, MAGE-A3/4, and NYESO-1 in cancerous and benign prostatic tissue. The Prostate2006; 66:13-18.
19. Jungbluth AA, Antonescu C R, Busam K J, et al. Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7. Int J Cancer 2001; 94:252-56.
20. Juretic A, Spagnoli G C, Schultz-Thater E, Sarcevic B. Cancer/testis tumour-associated antigens: immunohistochemical detection with monoclonal antibodies. Lancet Oncol 2003; 4:104-109.
21. Kurashige T, Noguchi Y, Saika T, et al. Ny-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: correlation with tumor grade. Cancer res 2001; 61:4671-74.
22. Fossa A, Berner A, Fossa S D, Hernes E, Gaudernack G, Smeland E B. NY-ESO-1 protein expression and humoral immune responses in prostate cancer. The Prostate 2004; 59:440-47.
23. Nakada T, Noguchi Y, Satoh S, et al. NY-ESO-1 mRNA expression and immunogenicity in advanced prostate cancer. Cancer Immun 2003; 3:10.